A novel proton nuclear magnetic resonance (1H NMR) method for determining the absolute content of ticagrelor was proposed. The ideal spectra were obtained on a Bruker Avance-300 spectrometer with deuterated methanol (CD3OD) as the solvent and sulfadoxin as the internal standard. The ticagrelor signals at δH 7.14 (2H, m) and δH 7.04 (1H, s), as well as those of sulfadoxin at δH 8.04 (1H, s), δH 7.73 (2H, d) and δH 6.54 (2H, d), were selected for quantitative analysis. The detection conditions were as following:probe temperature 308 K, spectrum width 3 511.5 Hz, center frequency 1 470.6 Hz, pulse angle θ=30°, delay time (d1) 10 s, number of scans 16 and line broadening 0.3 Hz. The signals from ticagrelor and internal standard sulfadoxin showed good separation, precision, reproducibility, and wide linearity ranges with Y=1.053X-0.081 (r=0.996, n=5). The content of ticagrelor was estimated to be 99.4% (RSD=0.20%). This method was proven simple, accurate and rapid.
[1] LIANG D W, DONG J H. Ticagrelor[J]. Chin J Med Chem, 2011, 21(6):509-510.梁大伟, 董金华. 替格瑞洛[J]. 中国药物化学杂志, 2011, 21(6):509-510.
[2] JAMES S, AKERBLOM A, CANNON C P, et al. Comparison of ticagrelor, the first reversible oral P2Y 12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes:rationale, design, and baseline characteristics of the PLATelet inhibition and patient outcomes (PLATO) trial[J]. Am Heart J, 2009, 157(4):599-605.
[3] YANG X W, ZHANG J Y, YI F, et al. Effect of ticagrelor on patients undergoing percutaneous coronary intervention with acute coronary syndrome[J]. Chin J Clinicians, 2013, 7(19):8696-8670.杨晓伟, 张君毅, 易甫, 等. 替格瑞洛对急性冠状动脉综合征择期介入治疗患者近中期疗效观察[J]. 中华临床医师杂志, 2013, 7(19):8696-8670.
[4] MA Y Y, WANG Y X, XU B G, et al. Short term clinical efficacy and safety of ticagrelor in patients received percutaneous coronary intervention[J]. Chin J Intervent Cardiol, 2014(6):380-383.马颖艳, 王艳霞, 徐白鸽, 等. 替格瑞洛用于经皮冠状动脉介入治疗术后患者抗血小板治疗短期内的有效性和安全性研究[J]. 中国介入心脏病学杂志, 2014(6):380-383.
[5] GURBEL P A, BLIDEN K P, BUTLER K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease[J]. Circulation, 2009, 120(25):2577-2585.
[6] ZHU Y H, JIA G L, ZHOU M, et al. Clinical effects of ticagrelor in 41 Chinese acute coronary syndrome patients[J]. Chin J Intervent Cardiol, 2013, 21(6):374-375.朱永宏, 贾国良, 周妙, 等. 替格瑞洛治疗41例急性冠状动脉综合征患者的临床疗效[J]. 中国介入心脏病学杂志, 2013, 21(6):374-375.
[7] TENG R, OLIVER S, HAYES M A, et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects[J]. Drug Metab Dispos, 2010, 38(9):1514-1521.
[8] SILLEN H, COOK M, DAVIS P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry[J]. J Chromatogr B, 2010, 878(25):2299-2306.
[9] HUANG P, GAO L, SIMA L, et al. The method improvement of determination of tetracycline tablets by HPLC[J]. Northwest Pharml J, 2014, 29(3):255-257.黄萍, 高林, 司马磊, 等. 高效液相色谱法测定四环素片含量的方法改进[J]. 西北药学杂志, 2014, 29(3):255-257.
[10] HU M, HU C Q, LIU W Y. Determination of drug reference substance content by 1H-nuclear magnetic resonance spectroscopy[J]. Chinese J Anal Chem, 2004, 32(4):451-455.胡敏, 胡昌勤, 刘文英. 核磁共振波谱法测定药物基准物质的绝对含量[J]. 分析化学, 2004, 32(4):451-455.
[11] GUO S Q, LIU M K, YU S, et al. A quantitative NMR method to analyze vitamin B1, vitamin B2, nicotinamide and calcium pantothenate contents in compound vitamin B tablets[J]. Chinese J Magn Reson, 2016, 33(3):442-451. 郭强胜, 刘明珂, 禹珊, 等. 定量核磁共振法同时测定复合维生素B片中B1、B2、烟酰胺和泛酸钙[J]. 波谱学杂志, 2016, 33(3):442-451.
[12] ZHANG M, ZHAI G Q, LI G Y, et al. An auto-processing algorithm for liver fat quantification[J]. Chinese J Magn Reson, 2018, 35(4):427-439.张苗, 翟国强, 李改英, 等. 定量肝脏脂肪的波谱自动后处理算法[J]. 波谱学杂志, 2018, 35(4):427-439.
[13] FLORES I S, GODINHO M S, DE OLIVEIRA A E, et al. Discrimination of biodiesel blends with 1H NMR spectroscopy and principal component analyses[J]. Fuel, 2012, 99:40-44.
[14] ZHANG F F, JIANG M H, SUN L L, et al. Quantitative determination of sitafloxacin hydrate by proton nuclear magnetic resonance (1H NMR)[J]. Northwest Pharml J, 2015, 30(2):137-141. 张芬芬, 蒋孟虹, 孙林林, 等. 核磁共振氢谱法(1H NMR)测定西他沙星标准物质的含量[J]. 西北药学杂志, 2015, 30(2):137-141.
[15] HOLZGRABE U. Quantitative NMR spectroscopy in pharmaceutical applications[J]. J Prog Nucl Magn Reson Spectrosc, 2010, 57(2):229-240.
[16] HOLZGRABE U, DEUBNER R, SCHOLLMAYER C, et al. Quantitative NMR spectroscopy-applications in drug analysis[J]. J Pharm Biomed Anal, 2005, 38(5):806-812.
[17] RABENSTEIN, D L, KEIRE, D A, POPOV, A I, et al. Practical spectroscopy[M]. New York:Marcel Dekker Inc., 1991:323-369.
[18] BEKIROGLU S, MYRBERG O, ÖSTMAN K, et al. Validation of a quantitative NMR method for suspected counterfeit products exemplified on determination of benzethonium chloride in grapefruit seed extracts[J]. J Pharm Biomed Anal, 2008, 47(4/5):958-961.
[19] ICH EXPERT WORKING GROUP. Validation of analytical procedures:Text and methodology Q2(R1)[M]//ICH Harmonized Tripartite Guidelines. 2005:1-13.
[20] GADAPE H H, PARIKH K S. Quantitative determination and validation of metformin hydrochloride in pharmaceutical using quantitative nuclear magnetic resonance spectroscopy[J]. J Chem, 2011, 8(2):767-781.
